Thomas Patrick Kelly - Oct 15, 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Chief Financial Officer
Signature: /s/ Nathaniel Adams, Attorney-in-fact
Stock symbol: XENE
Transactions as of: Oct 15, 2025
Transactions value $: $0
Form type: 4
Date filed: 10/17/2025, 06:43 PM
Previous filing: Jun 11, 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kelly Thomas Patrick	Chief Financial Officer	3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA	/s/ Nathaniel Adams, Attorney-in-fact	2025-10-17	0001410514

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XENE	Share Option (Right to Buy)	Award	$0	+225K		$0.00	225K	Oct 15, 2025	Common Shares	225K	$41.90	Direct	F1
transaction	XENE	Restricted Share Units	Award	$0	+30K		$0.00	30K	Oct 15, 2025	Common Shares	30K	$0.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Vesting 25% on October 15, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2	Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026.